Table 2.
Clinical and ultrasonographic parameters of the study population at baseline according to renal function outcome
| Benefit (n = 138) | Failure (n = 20) | |||
|---|---|---|---|---|
|
Clinical parameters |
|
|
||
|
Age (years) |
60.3 ± 10.3† |
67.8 ± 10.1 |
||
|
Male sex (%) |
63.5† |
88.9 |
||
|
BMI (Kg/m
2
) |
25.2 ± 3.6† |
27.5 ± 4.1 |
||
|
Current smoking (%) |
32.2 |
18.8 |
||
|
Previous cardiovascular events (%) |
28.7 |
37.5 |
||
|
Hypercholesterolemia (%) |
74.8 |
68.4 |
||
|
Diabetes (%) |
14.4 |
18.8 |
||
|
Hypertension duration (years) |
9.1 ± 8.5 |
6.1 ± 4.9 |
||
|
Systolic blood pressure (mmHg) |
161.7 ± 21.2† |
172.2 ± 21.0 |
||
|
Diastolic blood pressure (mmHg) |
91.5 ± 13.9 |
88.2 ± 13.8 |
||
|
Pulse pressure (mm Hg) |
70.5 ± 16.5† |
84.0 ± 14.9 |
||
|
Number of antihypertensive drugs |
2.1 ± 1.0 |
2.1 ± 1.0 |
||
|
RAS-blockers therapy |
72.2 |
100.0 |
||
|
Antithrombotic therapy (%) |
60.4 |
58.3 |
||
|
Cholesterol-lowering therapy (%) |
35.2 |
31.6 |
||
|
Serum creatinine (mg/dl) |
1.24 ± 0.42† |
2.06 ± 1.19 |
||
|
Creatinine clearance (ml/min) |
68.2 ± 25.6† |
50.2 ± 39.2 |
||
|
Estimated GFR (ml/min/1.73 m
2
) |
63.3 ± 18.9† |
45.3 ± 24.1 |
||
|
Albuminuria (mg/24 h) |
90.8 ± 282.8 |
295.3 ± 464.5 |
||
|
Ultrasonographic parameters |
Stenotic kidney |
Contralateral kidney |
Stenotic kidney |
Contralateral kidney |
|
Resistive index |
0.61 ± 0.11*† |
0.66 ± 0.09† |
0.72 ± 0.11* |
0.76 ± 0.08 |
|
Pulsatility index |
1.04 ± 0.31*† |
1.19 ± 0.29† |
1.36 ± 0.37* |
1.45 ± 0.34 |
|
Renal longitudinal diameter |
10.7 ± 1.3 |
10.8 ± 1.6 |
10.4 ± 1.3 |
10.2 ± 1.7 |
| Renal to aortic ratio | 4.3 ± 1.0* | 1.9 ± 1.1 | 3.8 ± 0.8* | 1.4 ± 0.9 |
*p < 0.05 vs contralateral kidney, †p < 0.05 vs failure group.